Long‐term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy‐naïve patients with metastatic castration‐resistant prostate cancer

• Published in: International journal of cancer Vol. 152; no. 6; pp. 1191 - 1201
• Main Authors: Chen, Hung‐Kai, Su, Po‐Jung, Wang, Yan‐Lin, Chang, Kai‐Cheng, Su, Yu‐Li, Chang, Pei‐Hung, Kuan, Feng‐Che, Hsieh, Chia‐Hsun, Kuo, Yung‐Chia, Sheng, Ting‐Wen, Chang, Ching‐Fu, Yu, Shao‐Ming, Huang, Wen‐Kuan, Lin, Yung‐Chang, Tsan, Din‐Li, Yu, Kai‐Jie, Lin, Po‐Hung, Chen, Hui‐Yu, Chang, Ying‐Hsu, Pang, See‐Tong, Chuang, Cheng‐Keng, Lai, Edward Chia‐Cheng
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.03.2023; Wiley Subscription Services, Inc
• Subjects: androgen receptor targeted therapies; Androgen receptors; Cancer; Cardiovascular Diseases; Castration; Chemotherapy; Electronic medical records; Heart; Humans; major adverse cardiac events; Male; Medical research; Metastases; Metastasis; metastatic castration‐resistant prostate cancer; Nitriles - therapeutic use; Patients; Prostate cancer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Response rates; Retrospective Studies; Survival; Treatment Outcome; major adverse cardiac events; metastatic castration-resistant prostate cancer; androgen receptor targeted therapies

This is a retrospective cohort study by analyzing a multi‐institutional electronic medical records database in Taiwan to compare long‐term effectiveness and risk of major adverse cardiac events (MACE) in chemotherapy‐naïve metastatic castration‐resistant prostate cancer (mCRPC) patients treated with...